Trial Profile
Phase 2 Trial of TAK-700 (Also Known as Orteronel) Without Prednisone for Metastatic Castration-Resistant Prostate Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Orteronel (Primary)
- Indications Prostate cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 06 Apr 2016 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017 as reported by ClinicalTrials.gov.
- 11 Aug 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 28 Oct 2013 Planned End Date changed from 1 Jun 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov.